Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against Mycobacterium tuberculosis
Fig 5
CD31 and α-SMA staining in the lung of infected mice treated with Marimastat.
(A): Mice infected with Mtb were treated with PBS (n = 5) or Marimastat (n = 5). Lung tissue from infected mice was stained for CD31 (upper panel) and α-SMA (lower panel). Both PBS and Marimastat groups had positive staining of CD31 and α-SMA. Scale bar: 80μm. (B, C, D): Quantification of CD31 positive blood vessel number (B), percentage of α-SMA positive staining (C), and α-SMA positive blood vessel number (D) in PBS or Marimastat treated mice (n = 5) 4-week post infection. Data represent mean ± SD. *: p < 0.05, **: p < 0.01, Two-tailed Unpaired Student t test with Welch-correction. (E, F): Quantification of percentage of α-SMA positive staining (E), and α-SMA positive blood vessel number (F) in consolidated area (granuloma like area) and surrounding normal tissue from PBS or Marimastat treated mice (n = 5) 4-week post infection. Data represented mean ± SD. *: p < 0.05, **: p < 0.01, One-way ANOVA with Šidák multiple comparison test.